Our goal is to perform biochemical simulations with chemical accuracy, where computation and experiment agree to within 0.5 kcal/Mol. We use Physics, Mathematics, Computer Science and Computational, Bio- and Organic Chemistry  to derive rules of biochemical interactions. We then use these rules to predict the properties and behavior of complex systems. We help solve real world problems in Pharmaceutical Ligand design, Biochemistry and Materials Science. We are incredibly fortunate to have three Nobel Laureates as our SAB and our management team. InterX is based in Berkeley, California.

  • Dr. Michael Levitt (Head, SAB)
    Dr. Levitt is currently a Professor of Structural Biology at Stanford University. He is known for developing the first software for molecular dynamics simulations of DNA and protein. In 2013, he received the Nobel Prize in Chemistry for the “development of multiscale models for complex chemical systems,” along with Martin Karplus and fellow board member Arieh Warshel. He is a member of the National Academy of Sciences and holds U.S., British, and Israeli citizenship.   wikipedia
  • Dr. Arieh Warshel
    Dr. Warshel is a Distinguished Professor of Chemistry and Biochemistry at the University of Southern California. He is regarded as the founder of computational enzymology and has received several awards, including the Nobel Prize in Chemistry in 2013. His innovations include the first molecular dynamics simulation of a biological process, microscopic electrostatic models for proteins, free energy perturbation in proteins, and other key advances. He is a U.S. and Israeli citizen and a Fellow of the American Association for the Advancement of Science and the Royal Society of Chemistry.   wikipedia
  • Dr. Richard Lerner
    Dr. Lerner is the former President of Scripps Research Institute and currently a member of Skaggs Institute for Chemical Biology. Under his presidency, Scripps grew to become one of the largest nonprofit biomedical research organizations in the world. He is also known for his pioneering work in converting antibodies into enzymes. He holds 67 patents and has published 403 scientific papers. In 2012, he shared the Prince of Asturis award for the conception and their development of combinatorial antibody libraries.   wikipedia
  • Dr. Gary Wilcox
    Dr. Wilcox is the current CEO of Cocrystal Pharma, as well as a former Professor of Microbiology at UCLA. He was Executive VP of Icos, where he played a key role in the development of Cialis. Dr. Wilcox also co-founded Ingene, guiding the company through an IPO and a successful merger with XOMA. He has served on NASDAQ, New York, and London stock exchange companies and is currently a director of the Daily Journal Corp. He received the American Cancer Society Faculty Research Award for his pioneering work in positive control of gene expression and has published over 70 scientific papers and developed 15 patents.   press
  • Dr. Roger Kornberg (Executive CEO)

Roger David Kornberg (born April 24, 1947) is an American biochemst and professor of of structural biology at School of Medicine. Kornberg was awarded the Nobel Prize in Chemistry in 2006 for his studies of the process by which genetic information from DNA is copied to RNA, “the molecular basis of Eukariotic transcripton”.  Wikipedia link.

Mr. Paul T. Marinelli

Dr. Phillip Frost

Dr. Gary Wilcox

Dr. Richard Lerner

Mr. Amnon Lorch

Mr. Dmitry Kolosov

CEO – Mr. Paul T. Marinelli

CSO / CTO – Dr. Boris Fain

Director, Science – Dr. Leonid Pereyaslavets

Director, Engineering – Oleg Butin